MONTREAL, CANADA -- (MARKET WIRE) -- November 08, 2006 -- ProMetic Life Sciences Inc. (TSX: PLI) (“ProMetic”) is pleased to announce its UK subsidiary ProMetic BioSciences Ltd (“PBL”) is to provide Octapharma AG with scale-up quantities of a Mimetic Ligand™ affinity adsorbent developed under the collaboration agreement announced January 5th 2005. As a part of this collaboration, PBL developed a novel synthetic affinity ligand using its Chemical Combinatorial Library® technology. Having demonstrated the new Mimetic Ligand™ adsorbent achieved the purification performance requirements for Octapharma’s new recombinant protein product, the project is now entering the final scale-up phase of the CAD $1.4 million programme. This will involve the production of multiple batches of adsorbent.
